Jozo Boras

Klinička bolnica Merkur

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Spomenka Ljubić

Klinička bolnica Merkur

ŽM

Željko Metelko

Klinička bolnica Merkur

Nikica Car

Klinička bolnica Merkur

Zdenka Turk

Klinička bolnica Merkur

Marijana Vučić Lovrenčić

Klinička bolnica Merkur

Antonela Ljubičić

Lea Duvnjak

University of Zagreb

ŽR

Željko Reiner

University Hospital Centre Zagreb

Anamarija Jazbec

University of Zagreb

Vinko Vidjak

University of Zagreb

Cooperative Institutions

University of Zagreb

Klinička bolnica Merkur

University Hospital Centre Zagreb

University of Sarajevo

Institut za Reumatologiju

Hrvatski zavod za javno zdravstvo

Sisters of Charity Hospital

Klinika za psihijatriju Vrapče

University of Cambridge

Ljubljana University Medical Centre

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

The effect of lowering and raising of catecholaminas and serotonine in the central nervous system and other organs upon the survival of mice poisoned by armine

D Potkonjak Jozo Boras P Stern

Raising (metalworking)

Cite

Citations (1)

Effect of a new antirheumatic upon pig arthritis.

PubMed (1973)

Jozo Boras Z. Foršek M Hadzimuratović Ivan Selak K Valjevac

Antirheumatic drugs

Source

Cite

Citations (4)

Lipoprotein(a) seems to be a marker associated with the metabolic syndrome in type 2 diabetes mellitus and with the progression of intima-media thickness

Jozo Boras Spomenka Ljubić Nikica Car Marijana Lovrenčić Vučić Željko Metelko

Intima-media thickness

Lipoprotein(a)

Source

Cite

Citations (0)

Comparison of antihyperglycemic effects of creatine and metformin in type II diabetic patients

Clinical and investigative medicine (2009)

Boris Ročić Nataša Bedernjak Bajuk Petra Ročić Diana S. Weber Jozo Boras

Purpose: To compare the antihyperglycemic effects of metformin and creatine in recently detected type II diabetics in a short-term clinical study. Methods: In a 14 day simmetrically randomized crossover study, recently detected type II diabetics received either creatine (2x3 g/day) or metformin (2x500 mg/day) for five days, followed by two days of washout, followed by cross-over to the opposite treatment for the next five days. Fasting and post-prandial (-15, 60, 90, 120, 180 and 240 min) blood glucose, insulin, c-peptide, creatine and lactate were measured every other day for the duration of treatment, and HbA1c only at the begining and at the end of the study. Results: Both creatine and metformin decreased glucose concentrations to similar levels at all time points vs. basal glucose values [-15, 60, 90, 120, 180, and 240 min]: 11.1±0.75 vs 9.1±0.55a vs 8.8±0.59b, 14.4±0.6 vs 12.9±0.47a vs 13.1±0.55a, 14.8±0.58 vs 13.0±0.46b vs 13.3±0.55a, 14.1±0.6 vs 11.9±0.42b vs 12.5±0.51a, 12.2±0.6 vs 9.6±0.36c vs 9.9±0.38c, and 10.1±0.47 vs 7.8±0.36c vs 8.4±0.4b; (aP < 0.05; bP < 0.01; cP < 0.001 vs. basal glucose values). Neither treatment altered insulin, c-peptide, or HbA1c. Lactate varied during the day, but never reached the upper level of the safety reference range. Conclusion: Short-term treatment with creatine and metformin elicits similar glucose lowering effects in recently detected type II diabetics. Further studies are necessary to determine the effect of creatine on long-term glucose and insulin regulation. Purpose: To compare the antihyperglycemic effects of metformin and creatine in recently detected type II diabetics in a short-term clinical study. Methods: In a 14 day simmetrically randomized crossover study, recently detected type II diabetics received either creatine (2x3 g/day) or metformin (2x500 mg/day) for five days, followed by two days of washout, followed by cross-over to the opposite treatment for the next five days. Fasting and post-prandial (-15, 60, 90, 120, 180 and 240 min) blood glucose, insulin, c-peptide, creatine and lactate were measured every other day for the duration of treatment, and HbA1c only at the begining and at the end of the study. Results: Both creatine and metformin decreased glucose concentrations to similar levels at all time points vs. basal glucose values [-15, 60, 90, 120, 180, and 240 min]: 11.1±0.75 vs 9.1±0.55a vs 8.8±0.59b, 14.4±0.6 vs 12.9±0.47a vs 13.1±0.55a, 14.8±0.58 vs 13.0±0.46b vs 13.3±0.55a, 14.1±0.6 vs 11.9±0.42b vs 12.5±0.51a, 12.2±0.6 vs 9.6±0.36c vs 9.9±0.38c, and 10.1±0.47 vs 7.8±0.36c vs 8.4±0.4b; (aP < 0.05; bP < 0.01; cP < 0.001 vs. basal glucose values). Neither treatment altered insulin, c-peptide, or HbA1c. Lactate varied during the day, but never reached the upper level of the safety reference range. Conclusion: Short-term treatment with creatine and metformin elicits similar glucose lowering effects in recently detected type II diabetics. Further studies are necessary to determine the effect of creatine on long-term glucose and insulin regulation.

Creatine

10.25011/cim.v32i6.10669

Cite

Citations (13)

Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: A four-year follow-up

Wiener klinische Wochenschrift (2010)

Jozo Boras Spomenka Ljubić Nikica Car Željko Metelko Mladen Petrovečki

Intima-media thickness

Lipoprotein(a)

10.1007/s00508-010-1318-0

Cite

Citations (12)

DIABETES AND CORONARY HEART DISEASE

Diabetologia Croatica (2002)

Jozo Boras Ivana Pavlić-Renar Nikica Car Željko Metelko

In the coming decades, the burden of cardiovascular diseases (CVDs) related to diabetes will increase substantially. Cardiovascular disease, which includes coronary heart disease (CHD), cerebrovascular disease, and peripheral vascular disease, is the leading cause of mortality in people with diabetes. Most diabetics die of CVD, and atherosclerosis accounts for some 80 percent of all diabetic mortality. Heart disease, particularly CHD, is a major cause of morbidity and mortality among patients with diabetes mellitus. CHD is much more common in diabetics than in the general population, affecting as many as 55 percent of these patients. Results from the Framingham Study found that the presence of diabetes doubled the age-adjusted risk for CVD in men and tripled it in women. Similar data have been reported by the Multiple Risk Factor Intervention Trial (MRFIT). A number of other observations have confirmed the increase in CHD in patients with diabetes mellitus.

Framingham Heart Study

Source

Cite

Citations (3)

Endogenous secretory receptor for advanced glycation endproducts (esRAGE) and AGEs/esRAGE ratio as biomarkers of atherosclerosis risk in type 2 diabetes

Diabetes (2012)

Zdenka Turk Spomenka Ljubić Jozo Boras

Objective Endogenous secretory receptor for advanced glycation endproducts (esRAGE) an isoform of soluble RAGE, acts as decoy for AGEs. We hypothesized ratio of AGE-to-esRAGE could be link to atherosclerosis in diabetes. To examine this issue, we compared serum levels of esRAGE and methylglyoxal-adduct as well as the AGE-to-esRAGE ratio between type 2 diabetic patients with and without established macrovascular disease. Patients and Methods Methylglyoxal-adducts, AGEs and esRAGE were measured in type 2 diabetes (n=130) and healthy controls (n=30). A history of macrovascular events (cardiovascular disease, cerebral vasculopathy or peripheral vascular disease) was recorded in 50 subjects. Results esRAGE levels were lower in type 2 diabetic patients compared with control subjects (0.330±0.197 vs. 0.458±0.074 ng/ml, p=0.003). In diabetic population es RAGE correlated positively with MG-adducts, HbA1c, BMI, and triglyceride, and inversely with CRP, LDL and homocystein. Multiple stepwise regression analysis was performed to determine which parameters best predicted the esRAGE level. Finally, urinary MG-adduct excretion (p<0.001), AGEs (p<0.001), and AGE/esRAGE (p<0.001, inversely) remained to be independently associated circulatory esRAGE. Multiple stepwise regression model was used to evaluate the relationship between macrovascular disease as a dependent variable, and metabolic and AGE- parameters as independent variables. Analysis pointed to LDL (β=0.40 P=0.0001), HbA1c (β=0.37 P=0.0007), AGE/esRAGE (β=0.31 P=0.007) and homocysteine (β=0.25 P=0.013) as significant independent contributors to diabetic macrovascular disease. Conclusion A decreased level of esRAGE may therefore be a biomarker of atherosclerosis acting as either a decoy receptor or another mechanism.

Macrovascular disease

Stepwise regression

Source

Cite

Citations (1)

Formation of methylglyoxal-adducts in plasma is associated with LDL and triglyceride level: implications for diabetic atherosclerosis

Diabetologia (2010)

Zdenka Turk Jozo Boras

Source

Cite

Citations (0)

New trends in classification, monitoring and management of cardiovascular diseases

Željko Reiner Mojca Stegnar Luigi M. Biasucci Ana Stavljenić-Rukavina V. Blaton

The Croatian Society of Medical Biochemists and Slovenian Association for Clinical Chemistry, together with the Forum of the European Societies of Clinical Chemistry, IFCC Europe have organized the second in a series of postgraduate weekend courses, at the Inter-University Centre Dubrovnik, promoting continuous postgraduate education of experts in clinical chemistry and laboratory medicine, and ensuring the laboratory knowledge harmonization, this time on human heart in particular. Although human heart has always been regarded as the seat of emotions, it is, in fact a highly precious pump that quite often operates without interruption for as long as a hundred years, however, it may also run into serious problems. Cardiovascular diseases have become the major cause of death and disability after age 35. Renowned experts from European countries have participated in this specialized course entitled New Trends in Classification and Management of Cardiovascular Disease covering the clinical and laboratory aspects of cardiovascular diseases,

Harmonization

Medical laboratory

Source

Cite

Citations (0)

Makrovaskularne komplikacije šećerne bolesti

Medix : specijalizirani medicinski dvomjesečnik (2009)

Jozo Boras Antonela Ljubičić

Source

Cite

Citations (0)